Overview

Prevention of Cefoperazone-induced Coagulopathy

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

Evaluating the effect of prophylactic doses of vitamin K in preventing the adverse effect of cefoperazone/sulbactam induced coagulopathy in critically ill patients.

Phase:

Phase 4

Details

Lead Sponsor:

Helwan University

Treatments:

Vitamin K